Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2004
Business Overview: DaVita Inc. operates dialysis centers and provides related services. The company reported approximately 100.5 million shares of common stock outstanding as of July 30, 2004. A three-for-two stock split was effected in June 2004, and all historical share data has been restated.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2004 | Six Months Ended June 30, 2004 |
|---|---|---|
| Net Operating Revenues | $551.6 million | $1,087.1 million |
| Operating Income | $96.5 million | $193.3 million |
| Net Income | $52.4 million | $105.3 million |
| Diluted Earnings Per Share | $0.50 | $1.02 |
| Cash and Cash Equivalents | $200.7 million (Balance Sheet) | N/A |
| Net Cash Provided by Operating Activities | N/A | $216.8 million |
| Total Debt (Long-term + Current) | $1,144.1 million | N/A |
| Effective Interest Rate | 3.93% | N/A |
Note: All dollar amounts in the table are in millions unless otherwise noted. Data derived from the Consolidated Statements of Income, Balance Sheets, and Cash Flows.
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 13% year-over-year for the quarter ended June 30, 2004, compared to the same period in 2003. This was driven by an 8% increase in the number of dialysis treatments and a 3% increase in the average reimbursement rate per treatment.
- Profitability: Net income rose 36% year-over-year for the quarter ($52.4 million vs. $38.5 million). Operating income increased 16% to $96.5 million.
- Expense Management: Patient care costs remained stable at 68% of revenues, down from 69% in the prior year quarter. General and administrative expenses decreased as a percentage of revenue from 9% to 8%.
- Debt Reduction: Debt expense decreased significantly to $11.3 million for the quarter, down from $19.5 million in the prior year quarter, due to lower average interest rates (3.8% vs. 5.1%) and lower average debt balances.
- Liquidity: Cash and cash equivalents increased from $61.7 million at year-end 2003 to $200.7 million at June 30, 2004, bolstered by strong operating cash flows.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2004 Projection: Management projects full-year 2004 operating income to be between $385 million and $400 million.
- 2005 Outlook: Expectations for 2005 operating income are flat to 6% higher than 2004 levels. However, management notes potential negative impacts of $15 million to $30 million annually due to proposed CMS policy changes regarding EPO utilization and the Medicare Modernization Act (MMA).
- Growth Strategy: The company expects non-acquired annual growth rates to remain in the 3% to 5% range. In July 2004, DaVita acquired 10 additional centers and entered a definitive agreement to acquire Physicians Dialysis, Inc. (PDI) for approximately $150 million.
Risks and Contingencies
- Government Investigations: The company is cooperating with the U.S. Attorney's Office and the HHS Office of Inspector General regarding a review of historical billing practices, financial relationships with physicians, and pharmaceutical services. Penalties could be substantial if wrongdoing is found.
- Reimbursement Risks: Approximately 42% of revenues come from private payors and 50% from Medicare. Declines in private payor rates or changes in Medicare composite rates (specifically regarding EPO and lab services) could materially reduce earnings.
- Pharmaceutical Costs: Amgen is the sole supplier of EPO. Price increases or the introduction of alternative drugs like Aranesp could reduce margins or revenue.
- Legal Proceedings: Ongoing third-party carrier reviews of Medicare reimbursement claims for the company's Florida and Minnesota laboratories remain unresolved, with potential for further recoveries or denials.
Investor Verification Checklist
- Regulatory Review Status: Verify the current status and potential financial exposure of the U.S. Attorney's Office and OIG investigations into billing and physician relationships.
- Medicare Policy Impact: Assess the finalization of CMS proposed policy changes regarding EPO utilization and the inclusion of ancillary services in the composite rate, which could impact 2005 revenue.
- Acquisition Integration: Monitor the closing and integration of the Physicians Dialysis, Inc. (PDI) acquisition and the associated $150 million cash outflow.
- Debt Covenants: Review the amended credit facility terms (Term Loan B and new Term Loan C) to ensure compliance with restricted payment covenants regarding acquisitions and share repurchases.
- Stock-Based Compensation: Evaluate the potential impact of the proposed FASB Statement on Share-Based Payment (effective Jan 1, 2005) on future net income and EPS.